Paradigm Biopharmaceuticals Ltd(PAR.AU)已正式签署一项具有约束力的兽药许可与供应协议,该协议涉及口服PPS与Cox-2抑制剂的组合疗法。这一重要合作标志着公司在兽药领域迈出关键一步,为动物医疗市场带来创新治疗方案。协议的签署不仅强化了Paradigm在生物制药行业的战略布局,也为其产品管线的多元化发展注入新动力。
Paradigm Biopharmaceuticals Ltd(PAR.AU)已正式签署一项具有约束力的兽药许可与供应协议,该协议涉及口服PPS与Cox-2抑制剂的组合疗法。这一重要合作标志着公司在兽药领域迈出关键一步,为动物医疗市场带来创新治疗方案。协议的签署不仅强化了Paradigm在生物制药行业的战略布局,也为其产品管线的多元化发展注入新动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.